KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) EBITDA Margin: 2010-2025

Historic EBITDA Margin for Pacira BioSciences (PCRX) over the last 16 years, with Sep 2025 value amounting to 3.54%.

  • Pacira BioSciences' EBITDA Margin rose 8631.00% to 3.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.80%, marking a year-over-year increase of 1514.00%. This contributed to the annual value of -10.47% for FY2024, which is 2346.00% down from last year.
  • Per Pacira BioSciences' latest filing, its EBITDA Margin stood at 3.54% for Q3 2025, which was down 24.48% from 4.69% recorded in Q2 2025.
  • Pacira BioSciences' 5-year EBITDA Margin high stood at 25.70% for Q2 2021, and its period low was -82.77% during Q3 2024.
  • In the last 3 years, Pacira BioSciences' EBITDA Margin had a median value of 7.91% in 2024 and averaged 1.30%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first slumped by 9,358bps in 2024, then skyrocketed by 8,631bps in 2025.
  • Quarterly analysis of 5 years shows Pacira BioSciences' EBITDA Margin stood at 2.65% in 2021, then slumped by 840bps to -5.75% in 2022, then surged by 2,405bps to 18.30% in 2023, then crashed by 511bps to 13.19% in 2024, then soared by 8,631bps to 3.54% in 2025.
  • Its last three reported values are 3.54% in Q3 2025, 4.69% for Q2 2025, and 1.18% during Q1 2025.